Unlock the power of proteomics for ADC Development

ProCan® Technologies now offers the TargetQuant^TM ADC Panel to support the development of ADCs across solid tumors.

Using mass spectrometry-based proteomics, ProCan Technologies quantitatively profiles protein abundance, including cell surface targets, across thousands of real-world, clinically annotated tumour samples representing both treatment naïve and relapsed disease. Building on this data and knowledge, ProCan Technologies has now developed a targeted panel to directly quantify ADC target expression, the TargetQuant^TM ADC Panel.

The TargetQuant^TM ADC Panel empowers you to:

• Validate Targets – Ensure your ADC target is consistently and abundantly expressed in relevant cancer types and provide target quantitation relative to our pan-cancer database.
• Off-target interactions – Quantify ADC target abundance in patient normal tissue samples to provide indications of potential off-target effects.
• Expand Indications – Identify additional tumor types with strong target expression.
• Prioritize with Precision – Screen and compare multiple candidate targets in a single, multiplexed assay, enabling efficient, evidence-based selection beyond the limitations of traditional IHC.
• Develop Biomarkers – Link protein abundance to histology, clinical outcomes, and co-expression patterns, supporting biomarker-driven trial design and patient stratification.